Bibliography
- 'Cancer Facts and Figures, 2004' American Cancer Society, New York, NY 2004.
- BYSTRYN J-C, SHAPIRO RL, ORATZ R: Cancer vaccines: clinical applications: partially purified tumor antigen vaccines. In: Biologic Therapy of Cancer, 2nd edition DeVita V Hellman S, Rosenberg SA, Lippincott JB (Eds), Philadelphia, PA, USA (1995):668–679.
- BALCH CM, BUZAID AC, SOONG SJ et al.: Final version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J. Clin. Oncol (2001) 19:3635–3648.
- BALCH CM, HOIUGHTON AN, SOBER AJ, SOONG SJ: Cutaneous Melanoma, 3rd edition. Quality Medical Publishing, Inc., St Louis, MS, USA.
- KIRKWOOD JM, STRAWDERMAN MH, ERNSTOFF MS et al.: Interferon alfa-26 adjuvant therapy of high risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684.1 Clin. Oncol (1996) 14: 7–17.
- LENS M, DAWES M: Inteferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials./ Clin. Oncol (2002) 20:1818–1825.
- GROMET MA, EPSTEIN WL, BLOIS MS: The regressing thin melanoma. A distinctive lesion with metastatic potential. Cancer (1978) 42:2282–2292.
- BYSTRYN J-C: Antibody response and tumor growth in syngeneic mice immunized to partially purified B16 melanoma associated antigens./ Immunol (1978) 120:96–101.
- LIVINGSTON PO, CALVES MJ, NATOLI EJ: Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells. J. Immunol (1987) 138:1524–1529.
- REYNOLDS S, CELIS E, SETTE A et al.:HLA-independent heterogeneity of CD8* T cell responses to MAGE-3, Melan Al MART-1, gp100, tyrosinase, MC1R and TRP-2 in vaccine-treated melanoma patients. J. Immunol (1998) 161:6970–6976.
- FERRONE S: Human tumor associated antigen mimicry by anti-idiotypic antibodies. In: Specific immunotherapy of cancer with vaccines. Bystryn J-C, Ferrone S, Livingston P (Eds), New York: Ann. IVY Acad. Sci. (1993) 690:214–224.
- BYSTRYN J-C, ZELENIUCH-JACQUOTTE A. ORATZ R, SHAPIRO RL, HARRIS MN, ROSES DF: Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin. Cancer Res. (2001) 7:1882–1887.
- SRIVASTAVA PK, AMATO RJ: Heat shockproteins: the 'Swiss Army Knife' vaccines against cancers and infectious agents. Vaccine (2001) 19(17-19):2590–2597.
- SLINGLUFF CL Jr, YAMSHCHIKOV G,NEESE P et al.: Phase I trial of a melanoma vaccine with gp100 (280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer Res. (2001) 7:3012–3024.
- MORTON DL, BARTH A: Vaccine therapy for malignant melanoma. CA Cancer]. Clin. (1996) 46:225–244.
- BERD D: M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Opin. Biol. Ther. (2002) 2:335–342.
- PARMIANI G, CASTILLI C, DALERBA P et al.: Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl Cancer Inst. (2002) 94(11):805–818.
- WEBER J, SONDAK VK, SCOTLAND R et al.: Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer (2003) 97:186–200.
- REYNOLDS SR, ZELENIUCH-JACQUOTTE A, SHAPIRO RL et al.: Vaccine-induced CD8* T cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. Clin. Cancer Res. (2003) 9:657–662.
- MILLER K, ABELES G, ORATZ R et al.: Improved survival of melanoma patients with an antibody response to immunization to a polyvalent melnaoma vaccine. Cancer (1995) 75(2):495–502.
- TAKAHASHI T, JOHNSON TD, NISHINAKAY et al.: IgM anti-ganglioside antibodies induced by melanoma cell bvaccine correlate with survival of melanoma patients. J. Invest. Dermatol (1999) 112:205–209.
- LIVINGSTON PO, WONG GY, ADLURI S et al.: Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. j Clin. Oncol (1994) 12: 1036–1044.
- ROSENBERG SA, YANG CJ, RESTIFO NP: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. (2004) 10(9):909–915.
- REYNOLDS SR, ALBRECHT J, SHAPIRO RL et al.: Changes in the presence of multiple markers of circulating melanoma cells correlates with clinical outcome in patients with melanoma. Clin. Cancer Res. (2003) 9:1497–1502.
- SOSMAN JA, UNGER JM, LIU PY et al.: Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J. Clin. Oncol (2002) 8:2067–2075.
- WALLACK MK, SIVANANDHAM M, BLACH CM et al.: Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a Phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. 1 Am. Coll Surg. (1998) 187:69–79.
- HERSEY P, COATES AS, MCCARTHY WH et al.: Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. Clin. Oncol. (2002) 20:4181–4190.
- KIRKWOOD JM, IBRAHIM JG, SOSMAN JA et al.: High-dose interferon alfa-26 significantly prolongs relapse-free and overall survival compared with GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/59512/C509801. 1 Clin. Onco/. (2001) 19:2370–2380.
- HSUEH EC, ESSNER R, FOSHAG LJ et al.: Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. 1 Clin. Oncol (2002) 20:4549–4554.
- PARDOLL D, ALLISON J: Cancer immunotherapy: breaking the barriers to harvest the crop. Nat. Med. (2004) 10(9):887–892.
Websites
- http://www.iddb.com
- http://www.nci.nih.gov